Team - Danube BioVentures

Patrick Aisher

Patrick Aisher is a serial entrepreneur who has invested in the life sciences industry since 1997. He has focused on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services, making over 40 direct investments.

Patrick has a broad portfolio, including various successful NASDAQ exits, two trade sale exits at $40M (KB Medical to Globus in 2018) and $150M+ (Medina Medical to Medtronic in 2016), and two exits via international licensing transactions valued at $350M+. He is a partner in a $200M venture fund for private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. Over the years, Patrick has cultivated strong relationships with key industry players, positioning himself as a significant figure in the venture capital landscape.

Patrick is a Director of Aleva Neurotherapeutics SA and PreComb Therapeutics AG, and has identified and invested in early-stage spin-off opportunities from universities in Barcelona, Zurich, Oxford, Boston, Stanford, Northeastern, Texas, NYU, Lausanne, and Geneva. His commitment to fostering innovation in the life sciences sector is reflected in his active involvement in mentoring and supporting emerging entrepreneurs, as well as his participation in various industry conferences and panels.

Patrick Aisher

Patrick Aisher is a serial entrepreneur who has invested in the life sciences industry since 1997. He has focused on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services, making over 40 direct investments.

Patrick has a broad portfolio, including various successful NASDAQ exits, two trade sale exits at $40M (KB Medical to Globus in 2018) and $150M+ (Medina Medical to Medtronic in 2016), and two exits via international licensing transactions valued at $350M+. He is a partner in a $200M venture fund for private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. Over the years, Patrick has cultivated strong relationships with key industry players, positioning himself as a significant figure in the venture capital landscape.

Patrick is a Director of Aleva Neurotherapeutics SA and PreComb Therapeutics AG, and has identified and invested in early-stage spin-off opportunities from universities in Barcelona, Zurich, Oxford, Boston, Stanford, Northeastern, Texas, NYU, Lausanne, and Geneva. His commitment to fostering innovation in the life sciences sector is reflected in his active involvement in mentoring and supporting emerging entrepreneurs, as well as his participation in various industry conferences and panels.

Patrick Aisher

Patrick Aisher is a serial entrepreneur who has invested in the life sciences industry since 1997. He has focused on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services, making over 40 direct investments.

Patrick has a broad portfolio, including various successful NASDAQ exits, two trade sale exits at $40M (KB Medical to Globus in 2018) and $150M+ (Medina Medical to Medtronic in 2016), and two exits via international licensing transactions valued at $350M+. He is a partner in a $200M venture fund for private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. Over the years, Patrick has cultivated strong relationships with key industry players, positioning himself as a significant figure in the venture capital landscape.

Patrick is a Director of Aleva Neurotherapeutics SA and PreComb Therapeutics AG, and has identified and invested in early-stage spin-off opportunities from universities in Barcelona, Zurich, Oxford, Boston, Stanford, Northeastern, Texas, NYU, Lausanne, and Geneva. His commitment to fostering innovation in the life sciences sector is reflected in his active involvement in mentoring and supporting emerging entrepreneurs, as well as his participation in various industry conferences and panels.

Stefanie Kearney

Stefanie Kearney brings nearly 20 years of experience in the life sciences and pharmaceutical industry to her role in the investment world. As a strategic advisor, she has been instrumental in liaising with shareholders, partners, and regulators.

Her background includes managing a contract laboratory for sterile manufacturing of patient-specific chemotherapy and antibody infusions at Medios Group, Germany’s first publicly traded speciality pharma company, based in Berlin. Her tenure there spanned from the company’s inception through its IPO and beyond, during which she obtained GMP licences for sterile production, clinical trial supplies, and pharmaceutical wholesale. Stefanie also established a digital decentralised laboratory specialising in non-destructive near-infrared spectroscopy for Medios Group and secured a narcotic drug licence for cannabis compounds.

Besides her business background, Stefanie holds a German licence as a pharmacist, having studied at Ludwig Maximilian University in Munich, and an executive master’s degree in digital healthcare from the University of Barcelona. This expertise aligns perfectly with her current role, where she leverages her deep industry knowledge to drive investments in groundbreaking healthcare technologies.

Stefanie Kearney

Stefanie Kearney brings nearly 20 years of experience in the life sciences and pharmaceutical industry to her role in the investment world. As a strategic advisor, she has been instrumental in liaising with shareholders, partners, and regulators.

Her background includes managing a contract laboratory for sterile manufacturing of patient-specific chemotherapy and antibody infusions at Medios Group, Germany’s first publicly traded speciality pharma company, based in Berlin. Her tenure there spanned from the company’s inception through its IPO and beyond, during which she obtained GMP licences for sterile production, clinical trial supplies, and pharmaceutical wholesale. Stefanie also established a digital decentralised laboratory specialising in non-destructive near-infrared spectroscopy for Medios Group and secured a narcotic drug licence for cannabis compounds.

Besides her business background, Stefanie holds a German licence as a pharmacist, having studied at Ludwig Maximilian University in Munich, and an executive master’s degree in digital healthcare from the University of Barcelona. This expertise aligns perfectly with her current role, where she leverages her deep industry knowledge to drive investments in groundbreaking healthcare technologies.

Stefanie Kearney

Stefanie Kearney brings nearly 20 years of experience in the life sciences and pharmaceutical industry to her role in the investment world. As a strategic advisor, she has been instrumental in liaising with shareholders, partners, and regulators.

Her background includes managing a contract laboratory for sterile manufacturing of patient-specific chemotherapy and antibody infusions at Medios Group, Germany’s first publicly traded speciality pharma company, based in Berlin. Her tenure there spanned from the company’s inception through its IPO and beyond, during which she obtained GMP licences for sterile production, clinical trial supplies, and pharmaceutical wholesale. Stefanie also established a digital decentralised laboratory specialising in non-destructive near-infrared spectroscopy for Medios Group and secured a narcotic drug licence for cannabis compounds.

Besides her business background, Stefanie holds a German licence as a pharmacist, having studied at Ludwig Maximilian University in Munich, and an executive master’s degree in digital healthcare from the University of Barcelona. This expertise aligns perfectly with her current role, where she leverages her deep industry knowledge to drive investments in groundbreaking healthcare technologies.